Argent BioPharma Ltd

Argent BioPharma (ASX: RGT) has signed a binding term sheet to acquire the key assets of AusCann Group Holdings, a deal designed to expand its clinical pipeline, intellectual property (IP) portfolio, and European presence. The US$15 million scrip-based transaction will see AusCann receive 25 million Argent shares at US$0.60 each, with completion expected in the […]

Argent BioPharma (ASX: RGT) has commenced the supply of a cannabinoid-based active pharmaceutical ingredient (API) to treat refractory (or drug-resistant) epilepsy patients at Slovenia’s largest hospital. The API will be transitioned to routine use at the paediatric clinic within University Medical Centre Ljubljana (UMCL) following a successful pilot program, enabling neurologists to dispense recommended, protocol-aligned […]

Argent BioPharma’s (ASX: RGT) flagship CannEpil cannabinoid-based therapy for the treatment of refractory (or drug-resistant) epilepsy has been approved for prescription in Germany under a special access scheme. The approval means that doctors can now prescribe the drug to eligible patients, who may also qualify for health insurance coverage depending on the doctor’s recommendation and […]

Argent BioPharma (ASX: RGT) has confirmed that pharmaceutical manufacturer ECCPharm will take on full production and release responsibilities for Argent’s emerging cannabinoid therapies under a strategic partnership between the two companies. The agreement will ensure the CannEpil and CogniCann treatments are available under early patient access programs in key European countries including Ireland, the UK […]